Core Insights - The 17th China Bio-Industry Conference opened in Wuhan, marking it as the largest and most influential professional event in China's bio-industry sector [1] - The conference showcased significant innovations, including the world's first plant-derived recombinant human serum albumin injection, Aofumin®, developed by Wuhan Heyuan Biotechnology Co., Ltd. [2] - The conference highlighted various groundbreaking products, including a visual intervention robot system and an implantable brain-computer interface chip, attracting considerable attention from attendees [5] Industry Developments - The conference featured the world's first clinical research candidate for oncolytic virus therapy, OH2 injection, developed by Wuhan Binhui Biotechnology Co., Ltd. [5] - The "China Bio-Economy Development Report 2025" was released, indicating that China's bio-economy industry remains the largest globally and is experiencing continuous growth [10] - Wuhan has established itself as a permanent host for the China Bio-Industry Conference since 2018, developing a comprehensive bio-pharmaceutical industry cluster with a scale exceeding 550 billion yuan [10]

Core Insights - The 17th China Bio-Industry Conference opened on September 4, focusing on "Biotechnology Empowering the Future, Biomanufacturing Reshaping the World" with an emphasis on "high-end, professional, international, and market-oriented" approaches [1] Group 1: Event Overview - The conference showcased numerous well-known companies presenting cutting-edge technologies, products, and applications, highlighting the latest advancements in the global bio-industry [1] Group 2: Exhibitor Highlights - BGI Genomics displayed tissue slices applied in spatiotemporal chips [3] - The Optics Brain-Computer Interface and near-infrared brain function imaging device from the Optics Valley Biocity exhibition area attracted significant attention from foreign guests [4] - United Imaging Healthcare presented a 5T magnetic resonance imaging system [6] - Heyuan Bio showcased recombinant human albumin injection (from rice) [7]

Core Insights - China has become the second largest biopharmaceutical market globally, meeting domestic demand while gradually participating in international market competition [1] - The report highlights China's leading position in areas such as research and development of biopharmaceuticals, brain-computer interfaces, and high-precision digital slicing [1] Industry Developments - In 2024, the National Medical Products Administration of China approved 93 new drugs, marking a five-year high, with China ranking second globally in the number of drugs under research [2] - Four Chinese companies made it to the top 25 global pharmaceutical companies in terms of R&D pipeline scale, setting a new historical record [2] - China published over 20,000 SCI papers in the medical equipment field in 2024, leading the world in research output [2] - The biopharmaceutical industry in China accounts for over 30% of global innovative drugs, research pipelines, and newly listed drugs [2] Economic Impact - The value of bio-based materials and chemicals has surpassed 1 trillion yuan, with the contribution of the bio-economy to GDP exceeding 7% [2] - China has established 23 biopharmaceutical industry bases, leading globally in the number of biotechnology patent applications and R&D personnel [2] International Collaboration - The conference attracted Cuba's largest state-owned pharmaceutical group, highlighting successful collaboration in biotechnology between China and Cuba [3] - Jointly developed drugs, such as the EGFR monoclonal antibody for cancer treatment, have benefited over 50,000 Chinese patients [3]

Group 1 - The 17th China Bio-Industry Conference highlighted that China has become the second-largest biopharmaceutical market globally, meeting domestic demand while gradually participating in international market competition [1] - The report indicates that China is in a leading position in areas such as biopharmaceuticals under research, brain-machine interfaces, and high-precision digital slicing [1] - The global focus on biomanufacturing and circular economy strategies is increasing, with significant funding for gene and cell engineering research, biomass utilization, and the development of bioproducts [1] Group 2 - In 2024, China approved 93 new drugs, the highest in five years, and ranks second globally in the number of drugs under research [2] - Four Chinese companies made it to the top 25 global pharmaceutical companies in terms of R&D pipeline scale, marking a historic achievement [2] - China leads the world in the number of SCI papers published in medical equipment, with over 20,000 papers in 2024, showcasing strong research resources and innovation capabilities [2] Group 3 - The National Development and Reform Commission reported that China has established 23 biomanufacturing bases, leading in biotechnology patent applications and R&D personnel [2] - The biopharmaceutical industry in China ranks second globally, with innovative drugs, research pipelines, and newly approved drugs accounting for over 30% of the global total [2] - The value of biobased materials and chemicals has surpassed 1 trillion yuan, with the contribution of the bio-economy to GDP exceeding 7% [2] Group 4 - The conference featured over 200 renowned institutions and companies, showcasing more than 1,000 products, including several global firsts [2] - Notable innovations included a multimodal sensing system for brain rehabilitation and a world-first 5.0T whole-body MRI system [3] - The collaboration between China and Cuba in biotechnology was highlighted as a successful partnership, with joint research and production benefiting both nations [3]